Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Immutep Ltd ADR

Healthcare US IMMP

0.394USD
-0.0127(3.12%)

Last update at 2026-06-04T17:59:00Z

Day Range

0.390.41
LowHigh

52 Week Range

1.583.33
LowHigh

Fundamentals

  • Previous Close 0.41
  • Market Cap348.11M
  • Volume435839
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.26886M
  • Revenue TTM3.93M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -32.75147M
  • Diluted EPS TTM-0.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -39.89635M -32.21079M -29.90259M -13.46819M -18.34398M
Minority interest - - - - 0.00000M
Net income -39.89635M -32.21083M -29.90262M -13.46823M -16.27064M
Selling general administrative 8.68M 7.21M 6.28M 6.34M 6.13M
Selling and marketing expenses - - - - -
Gross profit - 0.17M 3.97M 7.49M 0.14M
Reconciled depreciation - 3.00M - 2.08M 1.88M
Ebit -41.43131M -33.93755M -19.56058M -16.01888M -20.41733M
Ebitda - -31.87409M -20.72271M -13.93924M -18.53818M
Depreciation and amortization - 2.06M -1.16213M 2.08M 1.88M
Non operating income net other - - - - 0.00000M
Operating income -41.43131M -33.93755M -19.56058M -16.01888M -20.41733M
Other operating expenses - 34.01M 19.66M 22.56M 19.10M
Interest expense 0.02M 0.09M 0.00983M 0.01M 0.00000M
Tax provision 0.00000M 0.00005M 0.00003M 0.00004M 0.00000M
Interest income 0.94M 0.33M 0.11M 0.20M 0.40M
Net interest income 0.92M 0.19M 0.10M 0.19M 0.40M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense - 0.00003M 0.00003M 0.00004M -2.07334M
Total revenue 0.00000M 0.17M 3.97M 7.49M 0.14M
Total operating expenses 41.43M 34.01M 19.66M 22.56M 19.10M
Cost of revenue - - - - 0.64M
Total other income expense net 0.62M 1.73M -10.34201M 2.55M 2.07M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -39.89635M -46.82423M -29.90262M -13.46823M -18.34398M
Net income applicable to common shares -39.89635M -32.21083M -29.90262M -13.46823M -18.34398M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 147.45M 102.17M 82.03M 46.60M 40.54M
Intangible assets 9.38M 10.44M 12.74M 15.08M 16.84M
Earning assets - - - - -
Other current assets 0.05M 3.55M 7.83M 1.44M 1.74M
Total liab 10.98M 8.09M 8.76M 13.30M 16.15M
Total stockholder equity 136.47M 94.08M 73.27M 33.30M 24.39M
Deferred long term liab - - - - 0.00000M
Other current liab 4.14M 3.37M 3.31M 1.60M 2.74M
Common stock 446.27M 367.41M 313.42M 242.99M 221.09M
Capital stock 446.27M 534.09M 313.42M 242.99M 221.09M
Retained earnings -339.93053M -302.33521M -274.64222M -275.70606M -262.23783M
Other liab 0.16M 0.12M 0.81M 1.01M 3.21M
Good will 0.11M 0.11M 0.11M 0.11M 0.11M
Other assets 2.52M 0.50M 0.45M - 0.00000M
Cash 123.42M 80.00M 60.13M 26.32M 16.57M
Cash and equivalents - - - - -
Total current liabilities 9.77M 6.41M 5.34M 3.36M 5.30M
Current deferred revenue - - - - -
Net debt -122.18945M -78.26131M -57.31301M -17.27055M -8.92527M
Short term debt 0.19M 0.17M 0.21M 0.13M 0.00000M
Short long term debt - - - - 0.00000M
Short long term debt total 1.23M 1.73M 2.82M 9.05M 7.64M
Other stockholder equity 39.79M 38.67M 73.27M 33.30M 24.39M
Property plant equipment 0.47M 0.31M 0.31M 0.25M 0.05M
Total current assets 134.97M 90.81M 68.42M 31.15M 23.54M
Long term investments - - - - 0.00000M
Net tangible assets 126.98M 83.52M 60.42M 18.10M 7.44M
Short term investments - - - - 0.00000M
Net receivables 7.97M 8.37M 6.12M 3.39M 5.23M
Long term debt 0.84M 2.11M 2.53M 8.79M 7.64M
Inventory - -1.10832M -5.65941M - 0.00000M
Accounts payable 5.45M 2.87M 1.82M 1.64M 2.56M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 30.13M 29.00M 34.49M 66.01M 65.53M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 313.42M 233.33M 221.09M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 2.52M 0.50M 0.45M 15.19M 17.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 12.48M 11.36M 13.61M 15.45M 17.00M
Capital lease obligations 0.39M 0.41M 0.29M 0.26M 0.00000M
Long term debt total - - - - 7.64M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03100M -0.04500M -0.02400M -0.01935M -0.04143M
Change to liabilities 3.27M 1.44M 1.38M -2.12600M 1.40M
Total cashflows from investing activities -0.08274M -0.02291M -0.01560M -0.01935M -0.04143M
Net borrowings -0.21197M -0.22254M -0.21438M -0.07754M -0.07754M
Total cash from financing activities 76.04M 50.33M 52.68M 20.48M 8.01M
Change to operating activities -0.90011M -0.74727M -0.54342M 0.32M 0.02M
Net income -39.89635M -32.21083M -29.90262M -13.46823M -16.27064M
Change in cash 43.42M 19.40M 34.27M 9.75M -6.90754M
Begin period cash flow 80.00M 60.59M 26.32M 16.57M 23.48M
End period cash flow 123.42M 80.00M 60.59M 26.32M 16.57M
Total cash from operating activities -35.88300M -30.22975M -17.64034M -10.83934M -15.28640M
Issuance of capital stock 80.08M 52.98M 43.31M 22.03M 4.87M
Depreciation 2.06M 2.06M 2.07M 2.08M 1.88M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid 0.00000M 0.00000M - 0.00000M 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables -1.60770M -2.24938M -2.83054M 1.90M -0.06804M
Sale purchase of stock - - - - 8.79M
Other cashflows from financing activities -3.85600M -2.42715M 9.59M -1.47493M 3.14M
Change to netincome 1.71M 1.48M 12.18M 0.46M 1.29M
Capital expenditures 0.05M 0.02M 0.02M 0.02M 0.04M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital - -1.56119M - 9.75M -
Stock based compensation - 1.49M - - -
Other non cash items - -0.00804M 29.90M 11.39M 16.46M
Free cash flow -35.93000M -30.25267M -17.65594M -10.85869M -15.32783M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMMP
Immutep Ltd ADR		 -0.0127 3.12% 0.39 - 7.65 75.31 3.93 803.42 -5.552
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Immutep Ltd ADR

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Marc Voigt CEO, MD, CFO, Chief Bus. Officer & Exec. Director 1973
Ms. Deanne Miller LLB COO, Gen. Counsel & Joint Company Sec. 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer, Chief Medical Officer & Exec. Director 1955
Ms. Indira Naidu Joint Company Sec. NA
Mr. Christian Mueller Director of Clinical Devel. & Regulatory Affairs NA
Mr. Shengfei Fang Fin. Director & Assistant Company Sec. NA
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973
Ms. Deanne Miller LLB COO, General Counsel & Joint Company Secretary 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Executive Director 1955
Mr. Christian Mueller BBA, MSc. Senior Vice President of Regulatory & Strategy NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.